Key facts
- This page summarizes Kim Sablich's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jun 2023, 19:15.
Kim Sablich - 05 Jun 2023 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)
- Reporting relationship
- EVP, GM of U.S.
- Issuer ticker
- JAZZ
- Reported as of
- 05 Jun 2023
- Net transaction value
- -$270,098
- SEC form
- 4
- Accepted by SEC
- 07 Jun 2023, 19:15:12 UTC
- Prior SEC filing
- 10 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/Adam Guttmann, as attorney in fact For: Kimbely Sablich
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kim Sablich filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 07 Jun 2023.
Change
- Previous filing in this sequence was filed on 10 Mar 2023.
- Current net transaction value: -$270,098.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JAZZ
transaction
Ordinary Shares
Disposed to Issuer
- Transaction value
- $270,098
- Shares
- -2,082
- Change %
- -6.8%
- Price
- $129.73
- Shares after
- 28,478
- Date
- 05 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.